Farmas USA

Pues tio yo creo que hay que cazar los rebotes, pero con una máxima, cuando caigan sin motivo, El problema de puma son unos resultados cuestionables, y todo el mundo aprovecha para hacer sangre, con o sin razón, a pesar de los resultados todos los analistas le dan unas ventas acojonantes al Neratinib.

De gráficos no tengo ni idea, pero me parece que cuando hay noticias de por medio, los gráficos sirven de poco.

Espero que te suba cuanto antes.

Venga, IMMU, venga.....
Voluemn aumentando notablemente.....
Le está costando mucho decidirse a subir...
Parece que navegue a contra corriente....

IMMU

CHICAGO, June 2, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (IMMU) today announced an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate (ADC), labetuzumab govitecan, produced encouraging survival results in patients previously treated with at least one prior irinotecan-containing regimen for their metastatic colorectal cancer (mCRC).

For the 33 patients who received the ADC at the 8 or 10 mg/kg dose levels, the interim median progression-free survival (PFS), a measure of the length of time the patient is living without their disease getting worse from the beginning of their labetuzumab govitecan treatments, was 4.4 months, with 22% of these patients still benefiting from their cancer not progressing.

"Compared to what has been reported in the medical literature,1,2 this result is very encouraging for patients with mCRC," commented Dr. Efrat Dotan of Fox Chase Cancer Center, Philadelphia, PA, who presented the multicenter study at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) as one of the Principal Investigators.

In terms of treatment response, in 32 patients with at least one evaluation following treatments with labetuzumab govitecan at the 8 or 10 mg/kg level, 1 patient had a partial response and 24 patients reported stable disease as their best response, to give a combined disease control rate of 78%. Treatment response was evaluated in accordance with the rules set by the Response Evaluation Criteria In Solid Tumors (RECIST 1.1) using computed tomography as the imaging tool for tumor size measurements.

Labetuzumab govitecan was well tolerated by patients. At the optimal once-a-week doses of 8 and 10 mg/kg, grades 3 and 4 adverse events with occurrence of 5% or more included neutropenia (5% for both dose levels), and mild diarrhea (5% in the 8 mg/kg group only). Despite repeated dosing, no antibody against labetuzumab or its SN-38 conjugate was detected in blood samples from 74 patients over a 16-month period.

At the time of analysis, 87 patients have been enrolled to receive the ADC in the first 2 weeks of a 21-day cycle. In addition to the 8 and 10 mg/kg once-weekly dose, other dosing levels and schedule evaluated included 4, 6, 9, and 12 mg/kg, each at a frequency of twice a week.

Menos mal que las has ido cambiando...

Estais todos como una polla

PBYI

Pues ya no la cambio más, aunque me da que si baja del 150, podría tocar el 144 o algo así.

De 148 ya no me muevo.

Eso es igual a cerrar la posicion inicial pero pagando mas comisiones..

PBYI
Orden puesta a 145...a ver que nos depara

No lo se, Erdys, leo que ONTY es la verdadera razon por la que PBYI se esta dando el mamporro.

En fin ...